{"editorial":{"content_id":"4f0c9718-fbd3-4441-a373-b938ac5eb6aa","slug":"article-20261112-4dc9c2","content_type":"news","title":"巴西制药业首份普查：66%企业未来三年拟投研发，69%投技术设备","summary":"巴西制药业首份行业普查显示，未来三年66%的企业计划投资研发、69%计划投资技术设备，85%计划五年内扩大产品组合。","body":"巴西制药业正准备新一轮在科研、技术和产能方面的投资。巴西制药工业工会（Sindusfarma）与Datafolha研究所合作开展的首份制药业普查访问了168家企业，这些企业占巴西全国药品市场的89%。普查显示，未来三年66%的制药企业计划投资研发，69%计划投资技术设备。\n\n具体来看，54%的企业计划投资生产机器设备，51%计划投资厂房设施。产品组合方面，85%的企业预计在未来五年扩大治疗产品组合，同期年均复合收入增长预期为13%。\n\n技术转型同样是优先事项。在拥有巴西工厂的企业中，52%计划实施人工智能预测故障，49%计划数字化质量控制，48%计划将人工智能用于需求和产量预测。Sindusfarma执行总裁Nelson Augusto Mussolini表示：“66%的企业计划投资研发，这表明行业有意愿创新并扩大技术能力。”\n\n尽管投资计划明确，91%拥有巴西工厂的企业表示在生产中融入数字技术面临挑战，66%将高实施成本列为主要障碍。\n\n临床研究方面，65%的企业计划未来五年扩大投资，优先领域为肿瘤（26%）、中枢神经系统疾病（25%）和罕见病（22%）。监管方面，临床研究的伦理和监管平均审批时间为10.1个月，51%的企业认为审批期限过长是在巴西开展研究的主要障碍之一。","why_it_matters":null,"cbi_observation":null,"direction_tag":"巴西","primary_category":"科技平台","secondary_topics":["行业趋势","投资","科技","br-health"],"content_level":"编辑整理","event_type":"行业趋势","audience_tags":[],"event_location":null,"verification_status":"unverified","published_at":"2026-11-12T23:03:53.332Z","display_date":"2026-11-12","source_published_at":null,"source_url":"https://panoramafarmaceutico.com.br/censo-revela-prioridades-da-industria-farmaceutica/","source_name":"Panorama Farmacêutico","source_language":"pt","author_name":"编辑部","risk_level":"medium","risk_flags":[],"opportunity_flags":[],"trend_signals":[]},"intelligence":null,"meta":{"canonical_url":"https://chinabrazilinsight.com/news/article-20261112-4dc9c2","api_url":"https://chinabrazilinsight.com/api/public/content/article-20261112-4dc9c2","markdown_url":"https://chinabrazilinsight.com/api/public/content/article-20261112-4dc9c2?view=markdown","json_url":"https://chinabrazilinsight.com/api/public/content/article-20261112-4dc9c2?view=json","last_updated":"2026-11-12T23:04:16.875Z","platform":"China Brazil Insight","platform_url":"https://chinabrazilinsight.com"}}